Objectives: Reepot® is the world’s first target laser based on Q-switch 532nm, and control the hemoglobin chromophore that is related to side effects through a super-cooling control device by VSLS® technology

Introduction: In real-world clinical practice, selective photothermolysis (SPTL) is a relative theory because lasers are absorbed not only by the target chromophore but also by non-target chromophores, which can cause unwanted tissue reactions. These reactions are primarily due to an inflammatory response, which involves locally distributed cells. However, in reality, damage to the capillary loops located in the papillary dermis can result in vascular hemorrhage, migration of inflammatory cells, and persistent and systemic inflammatory responses by these migrated cells.

Materials / method: Vasculature Salvage Laser Surgery® is a combination of technologies that apply the theories and concepts explained above. Reepot® is the first q- switched 532nm laser to which VSLS® is applied. VSLS® system actively controls non-target chromophore through cryophotothermolysis® and a lesion recognition algorithm named Autoderm® in the aid of augmented reality head-mount apparatus.

Results: Complete clinical remission was observed in all cases of solar lentigo during follow-up. In cases where suspicious dermal melanophages were present, we performed additional treatment using q-switched lasers or alexandrite lasers rather than Reepot®.

Conclusion: With the the Reepot® Laser, the treatment frequency is expected to be greatly reduced while also minimizing side effects in the treatment of various pigmentation disorders, including solar lentigo, which are common but could be difficult to treat.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No
Please specify entities (individual, company, society): Medicare, Ilooda

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: Ilooda and Medicare